Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Mechanisms of hepatocellular carcinoma and cirrhosis development in concurrent steatotic liver disease and chronic hepatitis B

Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto

Clin Mol Hepatol. 2025;31(Suppl):S182-S195. Published online November 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0837

View: 1900 Download: 161 Web of Science: 1 Crossref: 1

Alcohol-associated liver disease: Natural history, management and novel targeted therapies

Edilmar Alvarado-Tapias, Elisa Pose, Jordi Gratacós-Ginès, Ana Clemente-Sánchez, Hugo López-Pelayo, Ramón Bataller

Clin Mol Hepatol. 2025;31(Suppl):S112-S133. Published online October 31, 2024

DOI: https://doi.org/10.3350/cmh.2024.0709

View: 2333 Download: 260 Web of Science: 1 Crossref: 4

Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease

Huma Saeed, Luis Antonio Díaz, Antonio Gil-Gómez, Jeremy Burton, Jasmohan S. Bajaj, Manuel Romero-Gomez, Marco Arrese, Juan Pablo Arab, Mohammad Qasim Khan

Clin Mol Hepatol. 2025;31(Suppl):S94-S111. Published online November 28, 2024

DOI: https://doi.org/10.3350/cmh.2024.0811

View: 4104 Download: 320 Web of Science: 4 Crossref: 6

Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Yue Wang, Sherlot Juan Song, Yichong Jiang, Jimmy Che-To Lai, Grace Lai-Hung Wong, Vincent Wai-Sun Wong, Terry Cheuk-Fung Yip

Clin Mol Hepatol. 2025;31(Suppl):S51-S75. Published online June 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0246

View: 6239 Download: 231 Web of Science: 3 Crossref: 3

Special Issue

KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025

Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang, on behalf of The Korean Association for the Study of the Liver (KASL)

Clin Mol Hepatol. 2025;31(Suppl):S1-S31. Published online February 19, 2025

DOI: https://doi.org/10.3350/cmh.2025.0045

View: 1189 Download: 148 Crossref: 2

Correspondence

Correspondence to editorial on “Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000-2021”

Pojsakorn Danpanichkul, Luis Antonio Diaz, Kanokphong Suparan, Karn Wijarnpreecha, Juan Pablo Arab

Clin Mol Hepatol. 2025;31(2):e200-e202. Published online February 17, 2025

DOI: https://doi.org/10.3350/cmh.2025.0166

View: 731 Download: 30

Editorial

Burden of alcohol use disorder, alcohol-related liver disease, and alcohol-related liver cancer: Editorial on “Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021

Youxin Wang, Noriko Oza, Jazleen Leo, Ashok Choudhury, Daniel Q. Huang

Clin Mol Hepatol. 2025;31(2):654-657. Published online February 10, 2025

DOI: https://doi.org/10.3350/cmh.2025.0133

View: 1060 Download: 60 Crossref: 1

Vibration-controlled transient elastography in shaping the epidemiology and management of steatotic liver disease: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023”

Xiao-Dong Zhou, Terry Cheuk-Fung Yip, Daniel Q Huang, Mark Dhinesh Muthiah, Mazen Noureddin, Ming-Hua Zheng

Clin Mol Hepatol. 2025;31(2):620-624. Published online December 26, 2024

DOI: https://doi.org/10.3350/cmh.2024.1131

View: 1426 Download: 60 Crossref: 2

Original Article

Global epidemiology of alcohol-related liver disease, liver cancer, and alcohol use disorder, 2000–2021

Pojsakorn Danpanichkul, Luis Antonio Díaz, Kanokphong Suparan, Primrose Tothanarungroj, Supapitch Sirimangklanurak, Thanida Auttapracha, Hanna L. Blaney, Banthoon Sukphutanan, Yanfang Pang, Siwanart Kongarin, Francisco Idalsoaga, Eduardo Fuentes-López, Lorenzo Leggio, Mazen Noureddin, Trenton M. White, Alexandre Louvet, Philippe Mathurin, Rohit Loomba, Patrick S. Kamath, Jürgen Rehm, Jeffrey V. Lazarus, Karn Wijarnpreecha, Juan Pablo Arab

Clin Mol Hepatol. 2025;31(2):525-547. Published online January 9, 2025

DOI: https://doi.org/10.3350/cmh.2024.0835

View: 3534 Download: 279 Crossref: 5

Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(2):382-393. Published online November 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0987

View: 3047 Download: 435 Crossref: 12

Correspondence

Correspondence to editorial on “Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis”

Young Eun Chon, Jung Hwan Yu, Seung Up Kim

Clin Mol Hepatol. 2025;31(1):e61-e63. Published online October 15, 2024

DOI: https://doi.org/10.3350/cmh.2024.0878

View: 1006 Download: 29

Correspondence to editorial on “Optimal cutoffs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis”

Jung Hwan Yu, Seung Up Kim

Clin Mol Hepatol. 2025;31(1):e52-e54. Published online September 24, 2024

DOI: https://doi.org/10.3350/cmh.2024.0815

View: 1041 Download: 30

Letter to the Editor

Letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”

Xiao-Song Li, Xi-Ping Shen, Hang Li

Clin Mol Hepatol. 2025;31(1):e15-e16. Published online September 12, 2024

DOI: https://doi.org/10.3350/cmh.2024.0784

View: 1005 Download: 42 Web of Science: 1 Crossref: 1

Editorial

The urgent need for multidisciplinary approaches in managing alcohol-associated liver disease: Editorial on “The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The UK Biobank cohort study”

Soon Sun Kim, Jae Youn Cheong

Clin Mol Hepatol. 2025;31(1):316-318. Published online October 7, 2024

DOI: https://doi.org/10.3350/cmh.2024.0847

View: 1050 Download: 54

Original Article

Optimal cut-offs of vibration-controlled transient elastography and magnetic resonance elastography in diagnosing advanced liver fibrosis in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis

Young Eun Chon, Young-Joo Jin, Jihyun An, Hee Yeon Kim, Miyoung Choi, Dae Won Jun, Mi Na Kim, Ji Won Han, Han Ah Lee, Jung Hwan Yu, Seung Up Kim

Clin Mol Hepatol. 2024;30(Suppl):S117-S133. Published online August 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0392

View: 3007 Download: 161 Web of Science: 4 Crossref: 5

Reply to Correspondence

Reply to correspondence on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”

Jae Hyun Bae

Clin Mol Hepatol. 2024;30(4):1047-1049. Published online August 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0666

View: 1496 Download: 57

Correspondence

The role of SPP1 in MASLD pathogenesis: Therapeutic insights into ursolic acid’s mechanisms of action: Correspondence to editorial on “Ursolic acid targets secreted phosphoprotein 1 to regulate Th17 cells against metabolic dysfunction-associated steatotic liver disease”

Yiyuan Zheng, Zhekun Xiong, Lina Zhao, Chaoyuan Huang, Qiuhong Yong, Dan Fang, Fengbin Liu, Yong Li

Clin Mol Hepatol. 2024;30(4):1019-1022. Published online July 8, 2024

DOI: https://doi.org/10.3350/cmh.2024.0471

View: 1809 Download: 61

Correspondence to editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”

Hayeon Kim, Min Jeong Park, Myeong Gyu Kim, Kyungim Kim

Clin Mol Hepatol. 2024;30(4):989-991. Published online August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0705

View: 1318 Download: 47 Crossref: 1

Letter to the Editor

Changing from NAFLD to MASLD: Cumulative incidence of gallstones between patients with NAFLD and those with MASLD in Asia

Shuhei Fukunaga, Tomoyuki Nakane, Michita Mukasa, Hidetoshi Takedatsu, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(4):959-961. Published online May 10, 2024

DOI: https://doi.org/10.3350/cmh.2024.0233

View: 1825 Download: 72 Web of Science: 5 Crossref: 5

Original Article

The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The UK Biobank cohort study

Keungmo Yang, Sunghwan Kim, Hyun Yang, Sheng-Min Wang, Bumseok Jeong, Hyun Kook Lim, Si Hyun Bae

Clin Mol Hepatol. 2024;30(4):929-942. Published online August 27, 2024

DOI: https://doi.org/10.3350/cmh.2024.0278

View: 2459 Download: 132 Crossref: 1

Editorial

Macrophage ATG16L1: Potential candidate for metabolic dysfunction-associated steatohepatitis treatment: Editorial on “Macrophage ATG16L1 expression suppresses metabolic dysfunction-associated steatohepatitis progression by promoting lipophagy”

Junjie Yu

Clin Mol Hepatol. 2024;30(4):721-723. Published online June 18, 2024

DOI: https://doi.org/10.3350/cmh.2024.0443

View: 1669 Download: 66 Web of Science: 1

Metabolic dysfunction-associated fatty liver disease is a ubiquitous latent cofactor in viral- and alcoholic-related hepatocellular carcinoma: Editorial on “Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis”

Toru Nakamura, Masahito Nakano, Tsubasa Tsutsumi, Keisuke Amano, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(4):705-708. Published online May 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0372

View: 2210 Download: 70 Web of Science: 3 Crossref: 3

Racial and ethnic disparities in metabolic dysfunction-associated steatotic liver disease outcomes: A call for culturally sensitive interventions: Editorial on “Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study”

Jae Hyun Bae

Clin Mol Hepatol. 2024;30(4):665-668. Published online July 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0562

View: 1709 Download: 91 Web of Science: 4 Crossref: 3

Letter to the Editor

Changing from NAFLD to MASLD: Prevalence and progression of ASCVD risk are similar between NAFLD and MASLD in Asia

Hiroyuki Suzuki, Tsubasa Tsutsumi, Machiko Kawaguchi, Keisuke Amano, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(3):577-579. Published online March 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0157

View: 3123 Download: 172 Web of Science: 10 Crossref: 8

Tsubasa Tsutsumi, Dan Nakano, Machiko Kawaguchi, Hirokazu Takahashi, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(2):266-268. Published online January 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0028

View: 2709 Download: 67 Crossref: 3

Snapshot

Recent updates on pharmacologic therapy in non-alcoholic fatty liver disease

Young Chang, Soung Won Jeong, Jae Young Jang

Clin Mol Hepatol. 2024;30(1):129-133. Published online October 13, 2023

DOI: https://doi.org/10.3350/cmh.2023.0356

View: 4262 Download: 182 Crossref: 7

Correspondence

Correspondence on Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”

Eileen L. Yoon, Dae Won Jun

Clin Mol Hepatol. 2024;30(1):126-128. Published online November 28, 2023

DOI: https://doi.org/10.3350/cmh.2023.0500

View: 2377 Download: 53

Correspondence on Letter regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Yee Hui Yeo, Ju Dong Yang

Clin Mol Hepatol. 2024;30(1):124-125. Published online November 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0470

View: 2538 Download: 56 Web of Science: 1 Crossref: 2

Letter to the Editor

Letter regarding “Waiting for the changes after the adoption of steatotic liver disease”

Kuo Chao Yew, Sunny H. Wong, Vincent Wai-Sun Wong, Hazel H. Oon

Clin Mol Hepatol. 2024;30(1):118-120. Published online November 14, 2023

DOI: https://doi.org/10.3350/cmh.2023.0472

View: 3008 Download: 67 Web of Science: 2 Crossref: 1

Letter 2 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”

Yiwen Zhang, Liwei Wu, Zepeng Mu, Linlin Ren, Ying Chen, Hanyun Liu, Lili Xu, Yangang Wang, Yaxing Wang, Susan Cheng, Yih Chung Tham, Bin Sheng, Tien Yin Wong, Hongwei Ji

Clin Mol Hepatol. 2024;30(1):113-117. Published online November 10, 2023

DOI: https://doi.org/10.3350/cmh.2023.0440

View: 3099 Download: 88 Web of Science: 5 Crossref: 4

1 | 2 | 3 | 4 | 5 | 6 | 7 |

Viewed By 10476	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7410	MAFLD: How is it different from NAFLD?
Viewed By 5352	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4782	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4764	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Cited By 338	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 305	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 210	MAFLD: How is it different from NAFLD?
Cited By 104	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis
Cited By 104	Non-alcoholic fatty liver disease: Definition and subtypes

Search